$VRAX

Virax Biolabs Group Ltd

Virax Biolabs is a biotechnology company focused on immune response detection, T cell immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases. It operates through subsidiaries in the United Kingdom, the United States and China. Its principal development platform, ViraxImmune™, is being developed to measure and characterize T cell responses and markers of immune dysfunction, initially for post-acute infection syndromes including Long COVID, ME/CFS and PTLD. The platform remains in development and is not authorized for diagnostic use. Virax Biolabs also develops and commercializes ImmuneSelect, a research-use-only range of peptide pools, ELISpot plates and related immune reagents for research laboratories, contract research organizations, biopharmaceutical companies, academic institutions and other research customers. It makes money through sales of these research-use products; its former distribution of third-party test kits under the ViraxClear and ViraxVet brands is no longer active. Virax Biolabs is headquartered at BioCity Glasgow in Newhouse, Lanarkshire, United Kingdom.

No enriched coverage for $VRAX in the last 7 days.

No SEC Form 4 filings for $VRAX in the last 30 days.

See all $VRAX insider activity →

NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'

Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS), and Arcturus Therapeutics (ARCT) surged 20%, 7%, 14%, and 13% respectively, following a Russian lab worker's death. Retail investors speculated about potential government contracts. Other related stocks like Alpha Pro Tech (APT), Lakeland Industries (LAKE), and NanoViricides (NNVC) also rose. The WHO and U.S. officials downplayed the risk, but traders anticipated increased preparedness spending.

RedChip Companies, Inc.: Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

RedChip Companies says it will air interviews on Bloomberg TV and CNBC featuring Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ). Virax CEO James Foster discusses post-fiscal 2026 balance sheet and Nasdaq bid compliance, plus ImmuneSelect supply talks. Transcode CEO Philippe Calais covers TTX-MC138 Phase 2a progress in ctDNA+ colorectal cancer.

VRAX sentiment & insider activity

Recent VRAX coverage spans financial news, market movers and corporate actions.

What's driving VRAX

AlphAI scores every news story that mentions VRAX with an AI model for sentiment and relevance, and aggregates insider trades from Virax Biolabs Group Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $VRAX

Score

NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'

Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS), and Arcturus Therapeutics (ARCT) surged 20%, 7%, 14%, and 13% respectively, following a Russian lab worker's death. Retail investors speculated about potential government contracts. Other related stocks like Alpha Pro Tech (APT), Lakeland Industries (LAKE), and NanoViricides (NNVC) also rose. The WHO and U.S. officials downplayed the risk, but traders anticipated increased preparedness spending.

RedChip Companies, Inc.: Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

RedChip Companies says it will air interviews on Bloomberg TV and CNBC featuring Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ). Virax CEO James Foster discusses post-fiscal 2026 balance sheet and Nasdaq bid compliance, plus ImmuneSelect supply talks. Transcode CEO Philippe Calais covers TTX-MC138 Phase 2a progress in ctDNA+ colorectal cancer.

Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch

Biotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.

Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

Virax Biolabs Group Limited (Nasdaq: VRAX) said it will immediately exercise certain preferred investment options to buy up to 548,000 ordinary shares at a reduced $6.00 exercise price, down from $10.00. The company expects about $3.3 million gross proceeds. It will issue new Series A and Series B options/warrants and expects closing around July 10, 2026, subject to conditions.

Why Did Virax Biolabs Stock Triple In One Session? - Virax Biolabs Group (NASDAQ:VRAX)

Virax Biolabs Group (NASDAQ:VRAX) shares surged 228.13% to $10.43 after the company announced an exclusive supply agreement with Fosun Diagnostics covering six Southeast Asian markets. The deal provides immediate product supply via purchase orders and targets near-term revenue, including tuberculosis-related RUO research in Thailand. VRAX also completed a 1-for-25 share consolidation.

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics

Virax Biolabs (NASDAQ: VRAX) said its subsidiary Virax Biolabs (UK) signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect RUO immune profiling products. The deal covers six Southeast Asian markets and enables near-term supply via purchase orders, with initial focus on tuberculosis research applications in Thailand. Fosun Pharma reported 2025 revenue of RMB41.662 billion (~US$5.8 billion).

Virax Biolabs stock surges 100% on Fosun supply deal By Investing.com

Virax Biolabs Group (NASDAQ:VRAX) shares jumped 100% after it signed an exclusive multi-country supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling products. The deal covers six ASEAN markets and enables immediate supply via purchase orders, with initial focus on tuberculosis research in Thailand. ImmuneSelect is research-use-only, separate from Virax’s in-development diagnostic platform.

Related tickers